Early research funded by the Children's Tumor Foundation has led to developments in schwannomatosis research. One award (2008) was for the development of the first mouse model for schwannomatosis with the same underlying gene mutations found in schwannomatosis patients. The second award (2011) was to support their use in a screening platform for schwannomatosis therapeutic agents.
Synodos for Schwannomatosis, an international consortium of clinicians and scientists from multiple disciplines, was launched at a full team meeting in Toronto, Canada on May 1, 2017. At the conclusion of this inaugural meeting, we met with the leaders of this exciting new consortium, who spoke candidly about the meeting, schwannomatosis research, and what is at stake for this important project.
On May 1, 2017, an international consortium of clinicians and scientists from multiple disciplines met in Toronto, Canada to officially launch the Synodos for Schwannomatosis project. Led by Dr. Gelareh Zadeh from University of Toronto and Dr. Laura Papi from University of Florence, Italy, the project aims to perform an extensive molecular analysis of schwannomatosis tumor samples to identify new therapeutic targets, and advance the understanding and management of the disease, with special focus on pain.
Your ongoing support has allowed us to take huge steps forward in 2016 in the fight against NF. Your efforts and contributions have been instrumental in advancing neurofibromatosis research, providing hope for the millions worldwide who live with NF, and bringing us ever closer to our shared goal of ending NF forever.
The Children’s Tumor Foundation is pleased to announce the launch of the 2017 Young Investigator Award (YIA). Interested candidates can submit their letters of intent, also referred to as pre-applications, via CTF’s online application portal from Dec 12, 2016 to Jan 9, 2017. Initiated in 1985, the YIA is CTF’s longest running award program and provides two-year salary support to outstanding early career scientists worldwide who are interested in becoming independent investigators in neurofibromatosis.